5.89
+1.03%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Cytek Biosciences
From its filings with the US Securities and Exchange Commission
Cytek Biosciences is based in Fremont, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker CTKB. The SEC classifies its business as laboratory analytical instruments. In the fiscal year to 31 December 2025, it reported revenue of $201.5m and a net loss of $66.5m. At that date it held total assets of $461.5m and shareholders' equity of $341.7m. By business, Product brought in 71.6% of revenue, followed by Service at 28.4%.
We are a leading cell analysis solutions company advancing the next generation of research and clinical tools with our novel technical approach of leveraging the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells (“Full Spectrum Profiling” or “FSP” technology). Our goal is to become the premier cell analysis company through continued innovation that facilitates scientific advances in biomedical research and clinical applications.
Biological systems are highly complex, and scientists are challenged by the multitude of questions that remain unanswered. Analysis at the single-cell level is essential to understand these complex systems. Identifying the correct cell in the context of a given biological question can have profound implications for drug development and health care decisions. It is essential to correlate information derived from multiple cell analysis approaches and to translate what is known at the gene level to the actual cell function. As a result, there is growing demand for deep content through high dimensional cell analysis and for solutions that can provide a complete picture of cellular biological processes and interactions. To achieve this, scientists need to phenotype and isolate rare events or unique populations down to the single-cell level through highly resolvable multi-dimensional cell analysis.
Quoted from its 10-K, filed 26 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Life Sciences Tools & Services
- Listed since
- 23 Jul 2021
- Employees
- 702
- Website
- cytekbio.com ↗
- Head office
- 47215 LAKEVIEW BOULEVARD, FREMONT, CA, 94538
- Incorporated in
- DE
- Classification
- Laboratory Analytical Instruments
- Filer status
- Accelerated filer
Leadership
Pay as last reported
- Dr. Wenbin JiangChairman of the Board, President, Chief Executive Officer, Co-Founder, since 2021$6.1m
- Dr. Ming YanCo-Founder, Chief Technology Officer, Director, since 2015$1.9m
- Mr. William MccombeChief Financial Officer$1.7m
- Dr. Philippe BusqueSenior Vice President, Global Sales and Services$1.0m
- Ms. Valerie BarnettChief Legal Officer and Corporate Secretary$2.4m
- Ms. Deborah NeffLead Independent Director$244,991
- Mr. Jack BallIndependent Director$284,991
- Mr. Michael HolderIndependent Director$339,997
- Dr. Vera ImperIndependent Director$244,277
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 30
- Environment
- 32
- Social
- 33
- Governance
- 24
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Cytek Biosciences Inc has a diverse range of high-quality products, including advanced flow cytometers and reagents. This enables the company to cater to the specific needs of different research and clinical applications.
- The company has developed innovative flow cytometry solutions that offer high-performance cell analysis, sorting, and imaging capabilities. This technological edge enhances Cytek Biosciences' competitive advantage in the industry.
- The field of biomedical research and diagnostics is expanding rapidly. The increasing demand for high-throughput and high-resolution cell analysis technologies provides Cytek Biosciences with significant growth opportunities.
Weaknesses
- Cytek Biosciences currently holds a relatively smaller portion of the flow cytometry market compared to established competitors. This limitation may lead to challenges in market penetration and brand recognition.
- The company relies heavily on research institutions as its major customer base. Any reduction in government funding or budget cuts to these institutions could have a negative impact on Cytek Biosciences' revenue.
Opportunities
- Expanding the company's presence in emerging markets, such as Asia and Latin America, can unlock new revenue streams. These regions show significant growth potential in biomedical research and diagnostics.
- Partnering with pharmaceutical companies can open doors to strategic collaborations and contract research projects. Such alliances can boost product development, increase market reach, and drive revenue growth.
Threats
- The flow cytometry market is highly competitive, with established players and new entrants constantly striving to gain market share. Cytek Biosciences faces the risk of aggressive pricing, technological advancements, and loss of market share to competitors.
- The company operates in an industry subject to strict regulatory guidelines. Any changes or updates to these regulations can pose challenges in terms of compliance, product approval, and time-to-market for Cytek Biosciences.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.